Overview
- Peptide (C)KYLYEDEG(S)WTRNS, corresponding to amino acid residues 288-301 of rat GLP1R (Accession P32301). 2nd extracellular, loop.
- Human THP-1 monocytic leukemia and MEG-01 megakaryoblastic leukemia cells.
Cell surface detection of GLP1R in live intact human THP-1 monocytic leukemia cells:___ Cells.
___ Cells + rabbit IgG isotype control-FITC (#RIC-001-F).
___ Cells + Anti-GLP1R (extracellular)-FITC Antibody (#AGR-021-F), (5 µg).
Cell surface detection of GLP1R in live intact human MEG-01 megakaryoblastic leukemia cells:___ Cells.
___ Cells + rabbit IgG isotype control-FITC (RIC-001-F).
___ Cells + Anti-GLP1R (extracellular)-FITC Antibody (#AGR-021-F), (5 µg).
Glucagon-like peptide 1 (GLP-1) is a hormone secreted by the intestine following a meal1. This hormone is known to enhance the secretion of insulin, important to regulate glucose blood levels2,3. In pancreatic b-cells, other than stimulating insulin secretion, GLP-1 action is also important for b-cell mass expansion2.
GLP-1 exerts its biological functions through Glucagon-like peptide 1 receptor (GLP-1 receptor), a member of the G-protein coupled receptor superfamily. Like all members this receptor spans the membrane seven times. GLP-1 receptor couples with Gs, thereby stimulates adenylate cyclase which consequently leads to an increase in cAMP2.
The receptor is expressed in various tissues, namely the pancreas, adipose tissue, muscle, heart, gastrointestinal tract and liver. GLP-1 receptor is also found in the central nervous system where it provides a neuroprotective effect4.
The glucagon-like peptide 1 system may serve as a therapeutic treatment in diabetes mellitus, in order to maintain b-cell mass expansion2. In addition, the receptor may serve as a therapy target in various neurodegenerative diseases like Alzheimer’s and Parkinson’s disease4.
